J. Lipid Res. Please sign the JLR Guestbook
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

A more recent version of this article appeared on September 1, 2006

Papers In Press, published online ahead of print June 1, 2006
J. Lipid Res., doi:10.1194/jlr.M600108-JLR200
This Article
Right arrow Full Text (Accepted Manuscript)
Right arrow All Versions of this Article:
M600108-JLR200v1
47/9/1908    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hu, Y.
Right arrow Articles by Zhang, X.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hu, Y.
Right arrow Articles by Zhang, X.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Submitted on March 6, 2006
Revised on April 25, 2006
Accepted on May 31, 2006

A systematic review and meta-analysis of the relationship between lipoprotein lipase Asn291Ser variant and diseases

Yaomin Hu, Wei Liu, Rong Huang, and Xiaoying Zhang

Division of Endocrinology, Department of Internal Medicine, Renji hospital, Shanghai Jiaotong University, Shanghai 200127

Corresponding Author: amin99{at}163.com

This systematic review attempted to summarize the associations between Asn291Ser variant in lipoprotein lipase (LPL) gene and dyslipidemia, the risk of type 2 diabetes mellitus (T2DM) and coronary heart disease (CHD). In addition, the relationships between Asn291Ser variant and other metabolic diseases such as obesity and high blood pressure were also investigated in this systematic review. We systematically reviewed the literature by means of a meta-analysis. Twenty-one articles including 19246 white subjects were selected for this meta-analysis. The summary standardised mean difference (SMD) of plasma triglyceride for carriers compared to non-carriers of Asn291Ser variant was 3.23 (p<0.00001). The summary SMD of plasma HDL-C for carriers compared to non-carriers of Asn291Ser variant was – 3.42 (p<0.0001). The summary SMD about the association of Asn291Ser variant with plasma triglyceride increased with the increasing age and weight gain. Significant interactions between LPL Asn291Ser variant and fasting glucose, T2DM and CHD were seen (P=0.02, 0.04, 0.01 respectively). No significant interactions were seen between LPL Asn291Ser variant and body mass index (BMI), waist-hip ratio (WHR), and blood pressure (P>0.05). This meta-analysis indicates that Asn291Ser variant in LPL gene is a risk factor for dyslipidemia, characterized by hypertriglyceridemia and low HDL-C levels. And Asn291Ser variant in LPL gene predisposes to more severe dyslipidemia with the increasing age and weight gain. Also, this meta-analysis shows that LPL Asn291Ser variant is associated with CHD and T2DM.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 All ASBMB Journals   Journal of Biological Chemistry 
 Molecular and Cellular Proteomics   ASBMB Today 
Copyright © 2006 by the American Society for Biochemistry and Molecular Biology.